ERBB2 and neoplasm: Our findings demonstrate that anti-HER2/neu TCR T cells exhibit antigen-specific cytotoxicity, preferentially targeting tumor cells with high HER2/neu expression while showing reduced activity against cells with lower expression, as evidenced by an in vitro cytotoxicity assay (See Figure 1).